<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>58</patient-age><report-id>PHHY2012BR096549</report-id><gender>female</gender><reactions><reaction>Heavy neck</reaction><reaction>Did not effect</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>DIOVAN AMLO FIX</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Hypertension</indication></indications><outcomes/><country>Brazil</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053167_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211134149</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>PHHY2012BR096549</safetyreportid>
		<primarysourcecountry>BR</primarysourcecountry>
		<occurcountry>BR</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2012-12-11</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-10-22</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2012-12-06</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012BR096549</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<linkedreport>
			<linkreportnumb>PHHY2012BR096543</linkreportnumb>
		</linkedreport>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>BR</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>ERS</patientinitial>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19540114</patientbirthdate>
			<patientsex code="2">Female</patientsex>
			<reaction>
				<primarysourcereaction>Heavy neck</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Neck rigidity</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Nuchal rigidity</reactionmeddrapt>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Did not effect</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Lack of drug effect</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Drug ineffective</reactionmeddrapt>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>DIOVAN AMLO FIX</medicinalproduct>
				<obtaindrugcountry>BR</obtaindrugcountry>
				<drugauthorizationnumb>21-990</drugauthorizationnumb>
				<drugauthorizationcountry>BR</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>1</drugstructuredosagenumb>
				<drugstructuredosageunit code="032"/>
				<drugdosagetext>1 DF, once (valsartan 320mg and amlodipine 12.5mg) a day</drugdosagetext>
				<drugdosageform normalized="tablet">Tablet</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Hypertension</drugindication>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>AMLODIPINE</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>VALSARTAN</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug ineffective</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug ineffective</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Nuchal rigidity</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Nuchal rigidity</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012BR096543 is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>spontaneous report from a patient (is a <Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">nurse</Semaphore>) received via Marketing Program (Vale Mais Saude; <Semaphore x="2684608" class="Occupation" value="Vendor" score="1.00" ID="C68608">Vendor </Semaphore>Voxline, ID 423) on 22 Oct 2012, with follow up information received from patient via Marketing Program (Vale Mais Saude; <Semaphore x="2684608" class="Occupation" value="Vendor" score="1.00" ID="C68608">Vendor </Semaphore>Voxline, ID 423) on 06 Dec 2012. This report refers to a 58- years old female patient. The patient received <Semaphore x="487197" class="Medicine - Diovan HCT - Dose" value="320mg" score="0.49" ID=""><Semaphore x="487234" class="Medicine" value="Diovan HCT" score="0.49" ID="248427">Diovan <Semaphore x="2013171" class="Procedure" value="Hematocrit Measurement" score="1.00" ID="C64796">HCT </Semaphore></Semaphore>320/12.5mg (<Semaphore x="1320437" class="Medicine" value="valsartan" score="0.74" ID="280295">valsartan </Semaphore><Semaphore x="2092495181709313" class="Medicine - Diovan HCT - Dose" value="320mg" score="0.49" ID="">320mg </Semaphore></Semaphore>
    <Semaphore x="5671143537115137" class="Medicine - valsartan - Frequency" value="and" score="0.74" ID="">and </Semaphore><Semaphore x="675434" class="Medicine" value="Hydrochlorothiazide" score="0.49" ID="270905">hydrochlorothiazide </Semaphore><Semaphore x="2900404299890689" class="Medicine - Hydrochlorothiazide - Dose" value="12.5mg" score="0.49" ID="">12.5mg</Semaphore><Semaphore x="2900683472764929" class="Medicine - Hydrochlorothiazide - Frequency" value=")" score="0.49" ID="">) </Semaphore><Semaphore x="1789915" class="AnatomicStructure" value="Coat" score="1.00" ID="C25450">coated </Semaphore>tablet for the <Semaphore x="1607549" class="Procedure" value="Blood Treatment" score="1.00" ID="C15657">treatment of <Semaphore x="3018504" class="MedDRA LLT" value="Hypertension" score="1.00" ID="10020772">high blood </Semaphore></Semaphore>
    <Semaphore x="2038093" class="Disease or Finding" value="Hypertension" score="1.00" ID="C3117">
     <Semaphore x="1607320" class="Disease or Finding" value="Blood Pressure Finding" score="1.00" ID="C54707">
      <Semaphore x="3018504" class="MedDRA LLT" value="Hypertension" score="1.00" ID="10020772">pressure</Semaphore>, </Semaphore></Semaphore>at a dose of once a day <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">orally </Semaphore>since an unspecified date (see case: PHHY2012BR096543). This medication was not the first that did not effect for her. She also used <Semaphore x="487291" class="Medicine" value="Diovan" score="0.74" ID="248426">Diovan </Semaphore>Amlo Fix 320/12.5mg (<Semaphore x="1320437" class="Medicine" value="valsartan" score="0.74" ID="280295">valsartan </Semaphore><Semaphore x="5671057637769217" class="Medicine - valsartan - Dose" value="320mg" score="0.74" ID="">320mg </Semaphore><Semaphore x="5671143537115137" class="Medicine - valsartan - Frequency" value="and" score="0.74" ID="">and </Semaphore><Semaphore x="103656" class="Medicine" value="Amlodipine" score="0.49" ID="239933">amlodipine </Semaphore><Semaphore x="444971496767489" class="Medicine - Amlodipine - Dose" value="12.5mg" score="0.49" ID="">12.5mg</Semaphore><Semaphore x="445083165917185" class="Medicine - Amlodipine - Frequency" value=")" score="0.49" ID="">) </Semaphore>for the <Semaphore x="1607549" class="Procedure" value="Blood Treatment" score="1.00" ID="C15657">treatment of <Semaphore x="3018504" class="MedDRA LLT" value="Hypertension" score="1.00" ID="10020772">high blood </Semaphore></Semaphore>
    <Semaphore x="3018504" class="MedDRA LLT" value="Hypertension" score="1.00" ID="10020772">pressure </Semaphore>at a dose of once a day since 3 years ago. The patient informed that the medication did not effect anymore, the medication did not <Semaphore x="2815272" class="MedDRA LLT" value="Blood pressure decreased" score="1.00" ID="10005734">decrease her <Semaphore x="1607320" class="Disease or Finding" value="Blood Pressure Finding" score="1.00" ID="C54707">blood pressure</Semaphore></Semaphore>. On an unspecified date (after starting <Semaphore x="487291" class="Medicine" value="Diovan" score="0.74" ID="248426">Diovan </Semaphore>Amlo Fix), the patient experienced heavy <Semaphore x="2263733" class="AnatomicStructure" value="Neck" score="1.00" ID="C13063">neck</Semaphore>. The events <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>was reported as recovered. The causality was reported as suspected.Follow up information received from patient via Marketing Program (Vale Mais Saude; <Semaphore x="2684608" class="Occupation" value="Vendor" score="1.00" ID="C68608">Vendor </Semaphore>Voxline, ID 423) on 06 Dec 2012: Updated suspect product information and event details (added new event: <Semaphore x="3146521" class="MedDRA LLT" value="Nuchal rigidity" score="1.00" ID="10058483">Nuchal rigidity</Semaphore>).</narrativeincludeclinical>
				<sendercomment>
Based on  Review of available reported data does not allow for a proper causality assessment. Reported event(s) is (are) unassessable</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>